Uterine Cervical Cancer
35
3
4
11
Key Insights
Highlights
Success Rate
69% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
5 terminated out of 35 trials
68.8%
-17.8% vs benchmark
6%
2 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (35)
Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).
Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304)
Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer
Detecting HPV DNA in Anal and Cervical Cancers
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes
Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy
Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer
Clinical Triage and Treatment of Atypical Glandular Cells (AGC) Detected in Screening
Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
A Multicenter Randomized Controlled Study of Photoelectric Detection in Cervical Cancer Screening
A Multicenter Real-world Study of Screening of Cervical Cancer Based on Photoelectric Detection
Three Birds With One Stone
Intended Use Study of the BD SurePath Plus™ Pap
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients
Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors
Adaptative Radiotherapy for Locally Advanced Cervical Cancer
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy